Paliperidon palmitát: praktické aspekty a doporučení
| Title in English | Paliperidone palmitate: practical aspects and recommendation |
|---|---|
| Authors | |
| Year of publication | 2012 |
| Type | Article in Periodical |
| Magazine / Source | Remedia |
| MU Faculty or unit | |
| Citation | |
| Field | Psychiatry, sexuology |
| Keywords | paliperidone palmitate; clinical recommendation; mechanism of action; metabolism |
| Attached files | |
| Description | Paliperidone palmitate is a depot formulation of paliperidone which is slowly released into the blood circulation. Paliperidone palmitate is an aqueous suspension produced using innovative NanoCrystal technology. Paliperidone is 9 OH risperidone that is a main active metabolite of risperidone. Paliperidone similarly like its mother molecule risperidone are associated with dopamine D2 and serotonin 5HT2A receptor antagonism. Paliperidone is active as an antagonist at alpha 1 alpha 2 adrenergic receptors and at histaminergic H, receptors. Paliperidone palmitate has characteristics that most clinicians and patients would find ideal in a depot medication: it does not require oral supplementation, uses a small gauge needle, involves a small injection volume and is administered monthly. The high acquisition cost of paliperidone palmitate will likely be an obstacle towards its widespread use. The reimbursement system in the Czech Republic will likely be an obstacle towards the widespread use of paliperidone palmitate. |
| Related projects: |